Goldman Sachs
BIOC

Goldman Sachs’s Biocept, Inc. BIOC Stock Holding History

Goldman Sachs’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-363
Closed -$3.71K – 6254
2023
Q1 		$3.71K Buy
+363
New +$5.25K ﹤0.01% 5821
2022
Q1 		– Sell
-703
Closed -$76K – 7061
2021
Q4 		$76K Buy
703
+68
+11% +$7.83K ﹤0.01% 6191
2021
Q3 		$76K Buy
+635
New +$74.1K ﹤0.01% 5963
2016
Q3 		– Sell
-1
Closed -$11K – 7244
2016
Q2 		$11K Buy
+1
New +$24.2K ﹤0.01% 6847

Other funds holding BIOC

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs's BIOC Position: Q2 2023 in Review

Goldman Sachs sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 363 shares — an estimated $3.71K sold.

Goldman Sachs first reported a position in BIOC in Q2 2016 and held it in 4 quarters. The position peaked at $76K in Q4 2021. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

  • Goldman Sachs reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 363 Biocept, Inc. shares in Q2 2023, an estimated $3.71K.
  • Goldman Sachs first reported a position in Biocept, Inc. in Q2 2016 and held it in 4 quarters.
  • Goldman Sachs's Biocept, Inc. position peaked at $76K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.